Submitted by Anonymous (not verified) on 19 September 2024 - 14:06
Opinion/decision on a Paediatric investigation plan (PIP): Praluent, Alirocumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism, PIP number: P/0550/2021
Source: